CHANGING THE COURSE OF MScongress.cnsfederation.org/course-notes/2017_Course...CHANGING THE COURSE OF MS HIGH EFFICACY THERAPEUTIC OPTIONS Sarah A. Morrow, MD, MS, FRCPC Fabrizio Giuliani,

CHANGING THE COURSE OF MS

HIGH EFFICACY THERAPEUTIC OPTIONS

Sarah A. Morrow, MD, MS, FRCPC Fabrizio Giuliani, MD

This program was developed by the CNSF, ANTIBODY Healthcare Communications and Hoffmann-La Roche and was planned to achieve scientific integrity, objectivity and balance.

LEARNING OBJECTIVES At the end of this session, participants will be able to:

• Recognize the impact of early disease activity on long-term outcomes in MS, andthe need for early, effective treatment

• Summarize the risk-benefit profile of current and emerging high efficacytherapies, and their impact on disease activity and progression

• Discuss best practices for implementing high efficacy therapies for optimaltherapeutic outcomes in MS

AGENDA

Time

12:45 pm – 1:00 pm (15 min)

Lunch

1:00 pm – 1:50 pm (50 min)

Program presentation

1:50 pm – 2:00 pm (10 min)

Case presentation & discussion

2:00 pm – 2:15 pm (15 min)

Q & A

SPEAKERS Sarah A. Morrow, MD, MS FRCPCDr. Morrow is Assistant Professor of Neurology in the Department of Clinical Neurological Sciences at Western University in London, Canada. She received her medical degree from the University of Calgary and completed her residency in neurology at the Western University, as well as a clinical Fellowship in MS in London, ON. She completed a 2- year research Fellowship on Cognition and MS at the Jacobs Neurological Institute in Buffalo NY with Dr. Ralph Benedict and received a Master’s degree in Epidemiology from the State University of New York at Buffalo. In addition to working in the MS clinic at London Health Sciences Center, in 2011 she established the first MS cognitive clinic in Canada. Her research interests are cognitive impairment in MS, relapses and corticosteroids treatment in MS.

Disclosures In the last two years, Dr. Morrow has received honoraria for speaking, consulting, and advisory board participation from Biogen Idec, EMD Serono, Genzyme, Novartis, and Roche. She has acted as site principal investigator for clinical trials for Novartis, Genzyme and Roche. She has received investigator initiated trial funding from Genzyme.

Fabrizio Giuliani, MD Dr. Fabrizio Giuliani is an MS neurologist and neuroimmunologist at the University of Alberta, Edmonton, Alberta. He is currently Associate Professor of Medicine at the same institution and the Medical Director of the Multiple Sclerosis Clinic. Dr. Giuliani earned his medical degree cum laude at the University of Bari School of Medicine, Italy where he also completed his residency in Adult Neurology. Dr. Giuliani’s research training was as an AHFMR clinical fellow at the University of Calgary, Calgary, Alberta under the guidance of Drs. Wee Yong and Luanne Metz. In 2006 Dr. Giuliani was the recipient of the prestigious Donald Paty Career Award from the MS Society of Canada. His research interests are focused on the mechanisms of neurodegenerative processes of multiple sclerosis and the development of new therapeutic strategies to prevent neuronal injury in inflammatory diseases of the CNS.

Disclosures In the last two years, Dr. Giuliani has received honoraria for speaking, consulting, and advisory board participation from Biogen Idec, EMD Serono, Genzyme, Novartis, Teva and Roche.

Notes: